Turmeric (Curcuma longa L.): A Comprehensive Reference
1. Identity, Botanical Classification, and Common Forms
1.1 Botanical Identity
Turmeric is a product of Curcuma longa, a rhizomatous herbaceous perennial plant belonging to the ginger family Zingiberaceae, which is native to tropical South Asia. Curcuma longa is a triploid species (2n = 3x = 63) belonging to the genus Curcuma. The turmeric plant needs temperatures between 20°C and 30°C and a considerable amount of annual rainfall to thrive. Individual plants grow to a height of 1 m and have long, oblong leaves. Plants are gathered annually for their rhizomes and are reseeded from some of those rhizomes in the following season.
As many as 133 species of Curcuma have been identified worldwide. Curcuma longa, the most well-known species of the Curcuma genus, is grown in warm climates and cultivated in tropical and subtropical regions worldwide. It is known by multiple names across cultures — turmeric in English, Haldi in Hindi, manjal in Tamil, kunyit in Indonesian, Jianghuang in Chinese, and Kyoo in Japanese.
1.2 Common Names and Regulatory Status
The Food and Drug Administration approved curcumin for use as an ingredient in various food categories as generally regarded as safe (GRAS). Curcumin is registered as a food additive under the code E100, used in sauces, soups, cheeses, baked goods, and certain beverages.
1.3 Commercial Forms and Preparations
Turmeric is commercially available in a wide range of forms. It is consumed in powder, juice, or extract form, or incorporated into culinary preparations, functional drinks, or dietary supplements. Nowadays, turmeric has been widely spread around the world and used as drugs, health foods, food additives, dietary supplements, and cosmetics. Turmeric, derived from the dried rhizome of Curcuma longa L., receives widespread attention because of its applications in pharmaceutical, food, cosmetic and other industries.
Standardized extracts represent the most common supplement form. The curcuminoid composition of the rhizome depends on many factors: botanical variety, soil, climate, harvest time, drying techniques, and extraction method. In a standardized turmeric extract, manufacturers ensure a consistent curcuminoid content, often between 95% and 98% for concentrated extracts used in health nutrition. Curcumin generally represents 75 to 80% of the total curcuminoids in crude turmeric extract.
To address the poor absorption of standard extracts (discussed in detail in Section 4), several enhanced-delivery commercial formulations have been developed. Different formulation techniques such as co-administration with piperine, incorporation into micelles, micro/nanoemulsions, nanoparticles, liposomes, solid dispersions, spray drying, and noncovalent complex formation with galactomannosides have been investigated. A phytosome formulation of turmeric extract, phosphatidylcholine, and microcrystalline cellulose (commercially known as Meriva) containing 18–22% curcuminoids is one commercially recognized example. Novel delivery systems such as liposomes, micelles, and nanoparticles significantly increase curcumin absorption and boost its therapeutic efficacy.
2. Historical and Traditional Use
2.1 Chronology and Geographic Spread
Turmeric has been utilized by humans for nearly 6,000 years. Historically, turmeric was widely used in Ayurveda medicine and traditional Asian medicine such as traditional Chinese medicine. According to records, the use of turmeric in India dated back roughly 6,000 years. It probably spread to both Morocco and China by around 700 AD, reached East Africa by 800 AD and West Africa by 1200 AD. Then in the thirteenth century, Arab merchants brought turmeric to Europe. Alternatively in the sixteenth century, turmeric entered Turkish cuisine, where it served as a natural coloring agent to give yellow color to saffron-infused rice dessert. Until the eighteenth century, turmeric was introduced to Jamaica.
Turmeric has been used in Asia for centuries and is a major part of Ayurveda, Siddha medicine, traditional Chinese medicine, Unani, and the animistic rituals of Austronesian peoples. It was first used as a dye, and then later for its supposed properties in folk medicine. In India, it spread with Hinduism and Buddhism, as the yellow dye is used to color the robes of monks and priests. In Maritime Southeast Asia, there is linguistic and circumstantial evidence of the ancient use of turmeric among the Austronesian peoples soon after dispersal from Taiwan (starting c. 3000 BCE), before contact with India. In Indonesia and the Philippines, turmeric was used for food, dyeing textiles, medicine, as well as body painting.
2.2 Ayurveda and Unani Medicine
Turmeric has a long history of use in traditional medicinal systems, particularly in Indian Ayurveda and Chinese traditional medicine, where it has been primarily employed for its anti-inflammatory, analgesic, and wound-healing properties. In Ayurveda, turmeric is regarded as a potent remedy for a variety of ailments, including digestive disorders, arthritis, skin diseases, and inflammatory conditions. Its rhizome is traditionally used to alleviate inflammation and pain, reflecting its role as a natural anti-inflammatory and analgesic agent.
In Unani and Ayurveda medicine, C. longa has been used for liver obstruction and jaundice, and has been applied externally for ulcers and inflammation. Additionally, it is employed in several other ailments such as cough, cold, dental issues, indigestion, skin infections, blood purification, asthma, piles, bronchitis, tumor, wounds, and hepatic disorders, and is used as an antiseptic.
In addition to treating internal inflammatory diseases, turmeric has been used topically in traditional formulations to promote wound healing and treat skin infections, leveraging its antimicrobial and anti-inflammatory properties.
2.3 Traditional Chinese Medicine
In Chinese medicine, turmeric is used to promote blood circulation, resolve blood stasis, and relieve pain, and is often prescribed for conditions involving stagnation and swelling. Traditionally, it has been widely used in Ayurveda medicine and traditional Asian medicine such as traditional Chinese medicine for treatment of digestive, respiratory, and circulatory diseases, as well as skin diseases.
3. Phytochemistry: Key Constituents and Active Compounds
3.1 Curcuminoids
Turmeric constituents include the three curcuminoids: curcumin (diferuloylmethane; the primary constituent and the one responsible for its vibrant yellow color), demethoxycurcumin, and bisdemethoxycurcumin, as well as volatile oils (tumerone, atlantone, and zingiberone), sugars, proteins, and resins.
Since its discovery, at least 235 phytochemicals, mostly terpenoids and phenolic molecules, have been identified from this herb — including 22 diarylheptanoids, 2 alkaloids, 4 sterols, 3 triterpenoids, more than 100 sesquiterpenes, 5 diterpenes, 68 monoterpenes, 8 phenylpropene and other phenolic molecules, and 14 other compounds.
Extensive research has confirmed that turmeric contains a variety of active ingredients, such as diphenylalkanoids, terpenoids, aromatics, steroids, fatty acids, minerals, and nucleosides.
Curcumin is the dominant curcuminoid. Curcumin (diferuloylmethane) is a naturally occurring polyphenol derived from the rhizome of Curcuma longa Linn., with potential for treatment of various diseases acting via NF-κB inhibition.
3.2 Volatile Oil Fraction
Curcumin, curcuminoids, ar-turmerone, α-turmerone, β-turmerone, and (Z) β-ocimene, α-phellandrene, terpinolene, 1,8-cineole, undecanol, and p-cymene are the major active constituents isolated from C. longa. The essential oil fraction, in particular the turmerones, has attracted separate research interest for neuroprotective and antimicrobial properties, although human clinical evidence for the isolated oil fraction is limited.
4. Bioavailability: A Central Pharmacokinetic Challenge
The most significant constraint on curcumin's clinical translation is its poor oral bioavailability. Due to its weak solubility and bioavailability, it has limited potential as an oral medication. Numerous factors including low water solubility, poor intestinal permeability, instability at alkaline pH, and fast metabolism contribute to curcumin's limited oral bioavailability.
Curcumin has low bioavailability due to its poor water solubility and absorption, rapid metabolism, and rapid systemic elimination. A study showed that 10 mg/kg of curcumin given intravenously to rats yielded a maximum serum curcumin level of 0.36 ± 0.05 μg/mL, whereas 500 mg/kg of curcumin administered orally only yielded a 0.06 ± 0.01 μg/mL maximum serum level in rats. The absorption of curcumin in this study was only about 1%.
In an independent crossover study assessing multiple commercial formulations, plasma levels of unconjugated curcumin remained below 2 nM in most cases, including high-dose and piperine combinations. The highest-performing formulation (NovaSOL) achieved levels of 6.7–38 nM at 30 minutes, but these were still 100-fold lower than concentrations used in vitro to show biological effects.
4.1 Piperine as a Bioavailability Enhancer
The most widely used strategy to improve absorption is co-administration with piperine, the active alkaloid of black pepper. This effect of piperine on the pharmacokinetics of curcumin has been shown to be much greater in humans than in rats. In humans, curcumin bioavailability was increased by 2,000% at 45 minutes after co-administering curcumin orally with piperine, whereas in rats, concomitant administration of piperine 20 mg/kg with curcumin 2 g/kg increased the serum concentration of curcumin by 154% for a short period of 1–2 hours post-drug. The study shows that in the dosages used, piperine enhances the serum concentration, extent of absorption, and bioavailability of curcumin in both rats and humans with no adverse effects.
However, independent pharmacokinetic research raises important caveats. Even when using a formulation with enhanced uptake, plasma levels of unconjugated curcumin remained minimal. In one study, piperine addition provided no additional benefit. Moreover, relying on excess purified piperine can be costly and may cause gastrointestinal discomfort and interfere with drug metabolism, leading to potential drug interactions.
A pharmacokinetic crossover trial in 30 healthy men and women compared five commercial curcumin formulations. Participants sequentially consumed single oral doses of a standard turmeric extract (1,500 mg), a liquid micellar preparation (1,000 mg), a piperine–curcuminoid combination (1,515 mg), a phytosome formulation (1,000 mg), or a dried colloidal suspension (300 mg). The standard extract contained 1,425 mg curcuminoids combined with 15 mg of a pepper extract standardized to 95% piperine; the liquid micellar preparation contained 60 mg curcuminoids. The micellar preparation delivered higher levels of total curcuminoids than any other formulation (8,540 ng·h/mL), reaching significance when compared with the dried colloidal suspension and standard extract (6,520 and 5,080 ng·h/mL, respectively). After dose normalization, both micellar and dried colloidal formulations showed significantly higher AUC levels than the standard extract.
5. Mechanisms of Action
5.1 Anti-inflammatory Pathways
As the principal bioactive constituent of turmeric, curcumin has been extensively investigated for its capacity to modulate multiple signaling pathways, including NF-κB, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase/Akt (PI3K/Akt) cascades, which play pivotal roles in regulating inflammatory responses, cellular proliferation, and apoptotic processes.
Curcumin exerts its core anti-inflammatory effects mainly by inhibiting the activation of the nuclear factor-κB (NF-κB) signaling pathway, regulating the mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) phosphorylation cascade, and regulating the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway.
It acts by inhibiting the NF-κB signaling pathway and reducing the production of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Additionally, curcumin mitigates oxidative stress by scavenging reactive oxygen species (ROS), thereby protecting cartilage from degradation.
Curcumin also suppresses the activity of COX-2 and LOX enzymes, which are responsible for producing inflammatory mediators including prostaglandins and leukotrienes. Through this mechanism, curcumin effectively curtails the production of these inflammatory molecules, thereby mitigating the inflammatory cascade.
5.2 Antioxidant Activity
Curcumin, a natural polyphenolic compound, exhibits broad research and application prospects due to its multi-dimensional regulatory effects on several key inflammatory pathways, including NF-κB, MAPK, JAK-STAT, and the NLRP3 inflammasome, as well as its potential therapeutic value in various inflammation-related diseases such as neurodegenerative disorders, inflammatory bowel disease, atherosclerosis, diabetes, and cancer.
5.3 Neuroprotective Mechanisms
Curcumin supplementation has been shown to restore brain-derived neurotrophic factor (BDNF) levels while regulating monoaminergic neurotransmission and mitigating multiple pathological processes including oxidative stress, neuroinflammation, β-amyloid aggregation, tau pathology, and aluminum-induced neurotoxicity in both Alzheimer's disease and depression models.
5.4 A Critical Caveat on Mechanism Research
In cultured cells, curcumin affects several cellular functions and some of the molecular targets have been identified; however, these events often occur only at concentrations that cannot be easily achieved in vivo. Scientific reports based on cell culture or animal studies are often not reproducible in humans. This gap between preclinical findings and clinical outcomes is a recurring theme throughout the turmeric research literature and should be borne in mind when interpreting mechanistic data.
6. Clinical Evidence by Area of Use
6.1 Musculoskeletal Conditions: Osteoarthritis and Arthritis
Osteoarthritis (OA) — particularly knee OA — is the most extensively researched indication for turmeric and curcumin in human clinical trials.
A 2025 critical review of systematic reviews and meta-analyses on curcumin for knee OA identified seven systematic reviews meeting inclusion criteria. Curcuminoids demonstrated potential efficacy and safety advantages over control treatments in KOA management. However, these reviews were of extremely low methodological quality, with poor reporting and significant information gaps. High risk of bias was noted in four SRs. Among 48 outcomes assessed, evidence quality was mostly low, with 5 medium-quality, 6 low-quality, and 37 extremely low-quality evidences. Significant literature overlap was also evident.
A 2025 systematic review and network meta-analysis searched PubMed, EMBASE, SCOPUS, and ClinicalTrials.gov up to August 2024 and included 17 studies. All turmeric preparations significantly reduced WOMAC pain. The mean differences (MD, 95% CI) for WOMAC pain reduction were −4.01 (–6.22, −1.80) for conventional curcuminoid preparations plus active drug comparators, −3.33 (–5.26, −1.39) for active comparators alone, −3.17 (–5.50, −0.83) for conventional curcuminoid preparations, and −2.47 (–3.27, −1.67) for bioavailability-enhanced curcuminoid preparations. The bioavailability-enhanced preparation demonstrated a 30% reduction in WOMAC pain compared to placebo, reaching the minimum clinically important difference threshold. The bioavailability-enhanced plus active comparator combination led to a 70% reduction in VAS pain compared to active comparator alone. However, all turmeric preparations appear to be effective in reducing knee OA pain when used as monotherapy compared to placebo; the certainty of evidence nonetheless remains low, indicating a need for further research.
A 2022 systematic review and meta-analysis in Frontiers in Immunology examined 29 RCTs involving 2,396 participants across five types of arthritis. Twenty-nine RCTs involving 2,396 participants and five types of arthritis — Ankylosing Spondylitis, Rheumatoid Arthritis, Osteoarthritis, Juvenile idiopathic arthritis, and gout/hyperuricemia — were included. Curcumin and Curcuma longa extract were administered in doses ranging from 120 mg to 1,500 mg for a duration of 4–36 weeks. The review noted that the RCTs included were at high risk of bias, and some RCT authors were funded by drug manufacturers or were employees, which may introduce bias.
A meta-analysis verified that curcumin/turmeric extract had treatment efficacy similar to NSAIDs based on findings from 16 RCTs and 1,810 adults.
Summary assessment: Multiple meta-analyses and systematic reviews support a statistically significant benefit of turmeric/curcumin in knee osteoarthritis for pain and function, with some evidence of comparable efficacy to NSAIDs. However, evidence quality is consistently rated as low to very low due to small sample sizes, high risk of bias in primary studies, methodological heterogeneity across formulations and doses, and frequent industry involvement.
6.2 Inflammatory Bowel Disease (IBD)
IBD, encompassing Crohn's disease and ulcerative colitis (UC), presents complex challenges in management due to dysregulated immune responses and genetic predispositions. The potential of curcumin as an adjunctive therapy in IBD has been assessed through systematic reviews of clinical trials.
A 2025 meta-analysis included 13 placebo-controlled RCTs on curcumin treatment in IBD after screening 362 records. Most trials focused on UC patients and were published post-2010, utilizing oral curcumin with varying dosages and durations. The analysis showed curcumin's significant efficacy in achieving clinical remission and response in UC patients, with heterogeneity observed.
Summary assessment: Evidence from RCTs suggests curcumin may be an effective adjunctive therapy in ulcerative colitis, primarily for maintaining or achieving remission. Evidence for Crohn's disease is more limited. Heterogeneity in formulations and doses limits firm conclusions.
6.3 Metabolic Syndrome, Glycemic Control, and Lipid Metabolism
Curcumin has anti-inflammatory, anti-oxidant, anti-diabetic, and anti-atherosclerotic properties, which can improve the metabolic parameters and symptoms of polycystic ovarian syndrome, metabolic syndrome (MetS), non-alcoholic fatty liver, and cardiovascular disease.
A 2025 systematic review and meta-analysis of RCTs specifically evaluating Curcuma longa in metabolic syndrome found: Curcumin supplementation significantly reduced fasting blood sugar (SMD = −0.54, 95% CI −0.72 to −0.36) and HbA1c (SMD = −0.41, 95% CI −0.60 to −0.23) in T2DM; decreased triglycerides (SMD = −0.48) and LDL cholesterol (SMD = −0.39) while elevating HDL cholesterol (SMD = 0.45) and total antioxidant capacity (SMD = 0.73). Curcuma longa also attenuated systemic inflammation, lowering C-reactive protein (SMD = −0.62), TNF-α (SMD = −0.57), and IL-6 (SMD = −0.50). Heterogeneity was moderate-to-high, reflecting differences in formulation, dosage, and duration. Collectively, these findings affirm that Curcuma longa exerts measurable, clinically relevant improvements on glycemic regulation, lipid metabolism, and inflammatory-oxidative balance; larger, long-term, multicenter RCTs are warranted to confirm durability, optimal dosing, and safety.
A 2024 review of meta-analyses published in Nutrients identified 54 meta-analyses of curcumin RCTs spanning inflammation, antioxidant status, glucose control, lipids, anthropometric parameters, blood pressure, endothelial function, depression, and cognitive function. A reduction in C-reactive protein (CRP) levels was observed in seven of ten meta-analyses of RCTs. In five of eight meta-analyses, curcumin intake significantly lowered interleukin-6 (IL-6) levels.
By 2021–2022, systematic reviews suggested that curcumin supplementation was associated with reductions in total cholesterol, triglycerides, and LDL-C, with modest or inconsistent effects on HDL-C depending on dose and population. More robust evidence emerged in 2023, when an umbrella review of RCTs demonstrated that curcumin significantly reduced TC, LDL-C, and TG while increasing HDL-C, particularly in individuals with metabolic disorders such as diabetes mellitus and metabolic syndrome.
Summary assessment: The weight of meta-analytic evidence supports a beneficial effect of curcumin on multiple cardiometabolic markers — fasting glucose, HbA1c, triglycerides, LDL-C, HDL-C, and inflammatory biomarkers (CRP, IL-6, TNF-α) — in individuals with metabolic syndrome and type 2 diabetes. Heterogeneity is consistently high, and effect sizes are modest. Evidence quality ranges from low to moderate.
6.4 Cognitive Function and Neurological Health
A single dose of a 10 g turmeric root extract formulation in aged individuals improved oxygenation and cerebral blood flow, which are associated with improving brain activity. In another study, taking 1,500 mg/day of BCM-95 (a turmeric oil-based curcumin formulation) for 12 months stabilized cognitive function in older adults when compared to a placebo, recipients of which showed reduced cognitive function over the same period.
Cognitive aging is a growing public health concern, and curcumin, a bioactive compound derived from turmeric, has been proposed as a potential intervention to support cognitive function due to its anti-inflammatory and antioxidant properties. A systematic review and meta-analysis aimed to evaluate the effects of curcumin on cognitive outcomes related to aging.
Summary assessment: Preclinical evidence for curcumin's neuroprotective effects is extensive, encompassing anti-amyloid, anti-tau, BDNF-restoring, and neuroinflammation-suppressing mechanisms. Preliminary human clinical trial data suggest possible benefits in cognitive aging and mood. However, the totality of clinical evidence remains early-stage, with most trials small and of short duration.
6.5 Depression and Mood
Curcumin supplementation has been shown to restore BDNF levels while regulating monoaminergic neurotransmission and mitigating neuroinflammation. Curcumin's potent antioxidant properties modulate stress responses, attenuating anxiety-like behaviors while preserving the cognitive-enhancing effects of acute stress. A growing number of RCTs have evaluated curcumin in depressive disorders; systematic reviews of these trials have generally found modest but statistically significant improvements in depressive symptom scores. However, as of the current evidence base, results are considered preliminary and effect sizes vary considerably between studies, constrained in part by the bioavailability limitations described above.
6.6 Cancer: Preclinical Promise, Limited Clinical Evidence
Pharmacological studies have confirmed the therapeutic value of curcumin in a variety of inflammation-related diseases, including neurodegenerative diseases, inflammatory bowel disease, atherosclerosis, diabetes, and tumors. Medicinal properties of turmeric (Curcuma longa L.), attributed to its polyphenolic curcuminoids, have given rise to extensive pre-clinical cancer research. Although "curcumin" supplements are a top-selling botanical with promising pre-clinical effects, questions remain regarding biological activity in humans.
Summary assessment: In vitro and animal studies have demonstrated anti-tumor activity across numerous cancer types through multiple mechanisms (NF-κB suppression, induction of apoptosis, anti-angiogenic effects). However, clinical trial evidence for cancer treatment or prevention in humans is very limited. Poor bioavailability after oral administration is widely cited as a major barrier to translating pre-clinical cancer findings into human efficacy. No curcumin formulation has received regulatory approval as an anti-cancer treatment.
7. Dosage Forms and Doses Reported in Clinical Studies
The following dosages are drawn directly from published clinical studies and are reported here strictly for reference purposes as used in the cited research:
- In a 2022 systematic review and meta-analysis of 29 RCTs in arthritis, curcumin and Curcuma longa extract were administered in doses ranging from 120 mg to 1,500 mg for a duration of 4–36 weeks.
- A turmeric extract standardized to 95% curcuminoids at 1,500 mg (1,425 mg curcuminoids) combined with 15 mg of pepper extract standardized to 95% piperine was one dose regimen studied in a pharmacokinetic crossover trial.
- A liquid micellar preparation containing 6% curcuminoids was administered at a dosage of 1,000 mg (60 mg curcuminoids) in 2 capsules in the same study.
- Supplementation with curcumin/piperine (500 mg–2 g/day curcumin plus 5–20 mg/day piperine) is one studied formulation range reported in IBD and muscle-related trials.
- In one pilot study, patients received 1,500 mg of highly bioavailable BCM-95 curcumin, supplied as two 750 mg softgels taken orally twice a day for 12 weeks; each softgel contained 500 mg of pure curcuminoids.
- Curcumin is reported to be safe orally at the dose of 6 grams per day for 4 to 7 weeks, based on clinical trial data.
- In a cognitive function trial, 1,500 mg/day of BCM-95 (a turmeric oil-based curcumin formulation) was administered for 12 months.
The wide variation in doses, formulations, and durations across studies makes direct comparison difficult and contributes substantially to the heterogeneity observed in meta-analyses.
8. Safety Considerations and Drug Interactions
8.1 General Safety Profile
Several trials on humans have not shown toxic effects, and curcumin is reported to be safe at the dose of 6 g/day orally for 4–7 weeks. However, some adverse events such as gastrointestinal disturbances have been reported.
The FDA approved curcumin for use as an ingredient in various food categories as generally regarded as safe (GRAS), and neither turmeric nor curcumin appears to worsen pre-existing liver conditions in therapeutic trial settings.
8.2 Drug-Induced Liver Injury (DILI)
Available evidence shows that there is a rare risk of liver injury from taking Curcuma longa (turmeric) and/or curcumin in medicinal dosage forms. The risk may be higher for products with enhanced absorption or bioavailability and/or higher doses. People with existing or previous liver problems may be more likely to develop this rare adverse event.
Isolated case reports and small case series of liver injury arising during use of turmeric dietary supplements have been published. Initially, these episodes were attributed to other exposures that might have accounted for the injury or possible contaminants in the commercial turmeric products. One reason given for the safety and lack of hepatotoxicity of curcumin was that it is poorly absorbed by the oral route, and it was unclear whether there was adequate systemic exposure to achieve any of the purported beneficial or adverse effects.
The role of piperine in hepatotoxicity risk is a key clinical concern. To enhance systemic absorption, many commercial formulations include piperine, an alkaloid derived from black pepper. Piperine inhibits hepatic and intestinal glucuronidation and can increase curcumin's bioavailability by up to 2,000%. However, this potentiation may also elevate the risk of hepatotoxicity, as reported in several recent cases involving turmeric-piperine combinations.
Clinically, DILI from turmeric-piperine often resembles acute viral hepatitis, with symptoms like significantly elevated aminotransferases, hyperbilirubinemia, fatigue, and pruritus. The latency period typically ranges from one to four months.
The causality assessment of turmeric-associated DILI is further complicated by the frequent presence of other hepatotoxic substances in commercial products. For instance, investigations have found lead chromate in certain turmeric products, which contribute to systemic and hepatotoxic risks. The additive or synergistic effects of such contaminants with curcumin may exacerbate liver injury and hinder a clear diagnosis of turmeric as the sole cause.
8.3 Drug Interactions: Cytochrome P450 and Piperine-Mediated Effects
Proposed mechanisms of curcumin's interactions include inhibition of cytokine signaling, eicosanoid synthesis, as well as tyrosine kinase, Janus kinase, and cytochrome P450 activity, among many others.
Some formulations incorporate additives like piperine, intended to inhibit ABCB1-mediated efflux for improving intestinal absorption and/or to inhibit metabolic enzymes like CYP450 and UDP-glucuronosyltransferases (UGT) for reducing conversion of curcumin into more polar conjugate metabolites. This CYP450 inhibition has direct implications for co-administered drugs. Piperine's inhibition of CYP3A4/P-gp has been shown to elevate plasma concentrations of co-administered drugs such as carbamazepine (by approximately 68.7%) and warfarin.
8.4 Gastrointestinal Effects
Gastrointestinal adverse events — including nausea, diarrhea, and stomach upset — are the most commonly reported side effects in clinical trials, particularly at higher doses. Serious adverse effects have not been reported with even high doses of curcumin in clinical trials. Mild adverse effects have been reported; however, these have been uncommon and resolved with curcumin dose reduction or discontinuation.
8.5 Contaminants in Commercial Products
Investigations have found lead chromate in certain turmeric products, which contribute to systemic and hepatotoxic risks. This underscores the importance of quality and purity standards in commercially available turmeric products and highlights a risk unrelated to the plant itself.
9. Body Systems and Health Areas of Association
Based on the accumulated clinical and preclinical literature, the following body systems and conditions have been subjects of turmeric and curcumin research:
- Musculoskeletal system: Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, exercise-induced muscle soreness
- Gastrointestinal system: Ulcerative colitis, Crohn's disease, dyspepsia, gastric health
- Metabolic and endocrine system: Type 2 diabetes mellitus, metabolic syndrome, obesity, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome
- Cardiovascular system: Dyslipidemia (total cholesterol, LDL, HDL, triglycerides), endothelial function, atherosclerosis
- Central nervous system: Cognitive aging, Alzheimer's disease models, depression, anxiety, neuroprotection
- Immune and inflammatory system: Systemic inflammatory marker reduction (CRP, IL-6, TNF-α), immunomodulation
- Hepatic system: Traditionally used for liver disorders; paradoxically, high-dose or bioavailability-enhanced supplement forms have been associated with rare DILI
- Oncology: Extensive preclinical anti-tumor activity; limited human clinical evidence
- Integumentary system: Traditional topical application for wound healing and skin infections
The relationship between C. longa and its constituent curcumin in terms of biological action includes antioxidant, anti-inflammatory, neuroprotective, anticancer, hepatoprotective, cardioprotective, immunomodulatory, antifertility, antimicrobial, antiallergic, antidermatophytic, and antidepressant properties.
10. Overall Evidence Summary
Medicinal properties of turmeric are attributed to its polyphenolic curcuminoids, where curcumin predominates. Although curcumin supplements are a top-selling botanical with promising pre-clinical effects, questions remain regarding biological activity in humans.
Considering all of the promising evidence to date, there is still a lack of supportive evidence especially from clinical trials on the adjunct use of C. longa and curcumin.
Curcumin's clinical application faces significant bottlenecks, primarily manifested in its inherent extremely low water solubility, poor bioavailability, and unfavorable pharmacokinetic profile. The field's central challenge — that concentrations shown to exert biological effects in laboratory settings may not be achievable in human systemic circulation after oral dosing — remains incompletely resolved, even with enhanced-delivery formulations. Interpreting the substantial body of positive meta-analytic evidence requires awareness of the predominantly low-to-very-low GRADE certainty ratings, frequent methodological limitations in primary studies, and the heterogeneity of the many distinct formulations studied under the umbrella term "curcumin."
References
- National Center for Complementary and Integrative Health (NCCIH/NIH) — Turmeric: Usefulness and Safety
- NIH LiverTox® — Turmeric (NCBI Bookshelf)
- Benzie IFF, Wachtel-Galor S (eds.) — Turmeric, the Golden Spice (Herbal Medicine: Biomolecular and Clinical Aspects, 2nd ed., NCBI Bookshelf)
- Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. — PMC
- Curcuma longa (turmeric): from traditional applications to modern plant medicine research hotspots — PMC / Springer Chinese Medicine
- Turmeric: A Comprehensive Review of Its Botany, Traditional Uses, Phytochemistry, and Mechanisms as a Functional Food — Nutrients (MDPI, 2026)
- Chromatographic Analysis of the Chemical Composition and Anticancer Activities of Curcuma longa Extract — PMC
- Anti-inflammatory Properties of Curcumin, a Major Constituent of Curcuma longa: A Review of Preclinical and Clinical Research — PubMed
- Regulation Mechanism of Curcumin Mediated Inflammatory Pathway and Its Clinical Application — PMC
- Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin — PMC
- Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials — PMC
- Pharmacokinetics of a Single Dose of Turmeric Curcuminoids Depends on Formulation: Results of a Human Crossover Study — PMC
- A Pharmacokinetic Study and Critical Reappraisal of Curcumin Formulations Enhancing Bioavailability — PMC
- A Critical Review of Systematic Reviews and Meta-Analyses of Curcumin for Knee Osteoarthritis — PMC / Frontiers in Pharmacology
- Effect of Turmeric Products on Knee Osteoarthritis: A Systematic Review and Network Meta-Analysis — PMC / BMC Complementary Medicine and Therapies
- Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis — PMC / Frontiers in Immunology
- Curcumin for the Clinical Treatment of Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis — PMC / Frontiers in Nutrition
- Effects of Dietary Polyphenol Curcumin Supplementation on Metabolic, Inflammatory, and Oxidative Stress Indices in Patients with Metabolic Syndrome — PMC / Frontiers in Endocrinology
- Clinical Potential of Curcuma longa Linn. as Nutraceutical/Dietary Supplement for Metabolic Syndrome: Systematic Review and Meta-Analysis — PMC
- Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses — Nutrients (MDPI)
- The Effects of Curcumin on Vascular Endothelial Function, Lipid Metabolism, Inflammation and Neuroprotection — PMC
- Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials — PMC
- Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials — PMC
- Potential Therapeutic Benefits of Curcumin in Depression or Anxiety Induced by Chronic Diseases: A Systematic Review — PMC
- Anti-inflammatory Effect of Curcumin on Neurological Disorders: A Narrative Review — PMC
- Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN] — The American Journal of Medicine
- Therapeutic Goods Administration (TGA) — Medicines Containing Turmeric or Curcumin: Risk of Liver Injury
- Drug-Induced Liver Injury Secondary to Turmeric Supplement Containing Piperine: A Case Report — PMC
- Drug-Induced Liver Injury Associated With Turmeric and Black Pepper-Based Dietary Supplements Consumption — PMC
- Turmeric-Associated Drug-Induced Liver Injury — PMC
- Effect of Curcumin Plus Piperine on Redox Imbalance, Fecal Calprotectin and Cytokine Levels in IBD Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial — PMC
Go back